No Data
Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial
Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
Arcellx Is Maintained at Buy by Stifel
Arcellx Is Maintained at Buy by Stifel
Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.
Stifel: Maintaining the Arcellx (ACLX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $82.00 to $83.00.
Stifel Maintains Buy on Arcellx, Raises Price Target to $83
Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.
Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Analyst Expectations For Arcellx's Future
During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she